Most cited article: Drug Targeting and Conventional Treatment of Multiple Myeloma: Analysis of Target-specific Nanotherapies in Disease Models

Author(s): Christina TranEden ParkPedro L. Rodriguez Flores and Robert B. Campbell*


Extensive studies have explored potential therapies against multiple myeloma (MM), whether in hospitals, universities or in private institutional settings. Scientists continue to study the mechanism(s) underlying the disease as a basis for the development of more effective treatment options. There are many therapeutic agents and treatment regimens used for multiple myeloma. Unfortunately, no cure or definitive treatment options exist. The goal of treatment is to maintain the patient in remission for as long as possible. Therapeutic agents used in combination can effectively maintain patients in remission. While these therapies have increased patient survival, a significant number of patients relapse. The off-target toxicity and resistance exhibited by target cells remain a challenge for existing approaches. Ongoing efforts to understand the biology of the disease offer the greatest chance to improve therapeutic options. Nanoparticles (targeted drug delivery systems) offer new hope and directions for therapy. This review summarizes FDA-approved agents for the treatment of MM, highlights the clinical barriers to treatment, including adverse side effects normally associated with the use of conventional agents, and describes how nanotherapeutics have overcome barriers to impede conventional treatments.

Learn more:

Editor’s Choice – A Comprehensive Review on Nanotechnological Approaches for Enhanced Delivery of Nutraceuticals in the Management of Osteoporosis

Author(s):Nisha SinghShatabdi DeyBhumika Kumar* and Pravat Kumar Sahoo

Volume 12, Issue 2, 2022

Published on: 02 June, 2022

Page: [96 – 108]

Pages: 13

DOI: 10.2174/2210303112666220414100934


Osteoporosis is a chronic, progressive bone condition that is most prevalent in postmenopausal women and the elderly population. An imbalance in the natural bone remodeling process, which is involved in the formation of bone and resorption, is responsible for osteoporosis, leading to bone fragility. It shows no clinical manifestation until a fracture takes place. Osteoporosis is a global epidemic that reduces the quality of life, increases the chances of disabilities, and adds on a huge financial load. Early diagnosis and treatment can help in preventing the disease. Several drug regimens are used in treating the condition; however, the drugs are accompanied by several adverse effects. Nutraceuticals, like herbs, minerals, vitamins, and dairy products, support skeletal strength and integrity. Therefore, the use of different types of nutraceuticals can improve overall bone strength and provide improved treatment of osteoporosis. The review paper focuses on providing indepth knowledge about the various nutraceuticals that are used in the management of osteoporosis along with the novel nanotechnology-based delivery approaches for enhanced delivery of nutraceuticals as the advent of nanotechnology in pharmaceuticals have opened new avenues in the challenging arena of nutraceuticals for providing benefits like stability, higher efficiency, solubility, enhanced bioavailability, permeability, and production without additives. Read now:

Editors Choice – Nano Technological Approaches for Anti-tumour Therapy: Opportunities and Challenges

Author(s):Krishna Champaneria* and Prajesh Prajapati

Volume 11, Issue 1, 2021

Published on: 13 February, 2020

Page: [1 – 13]

Pages: 13

DOI: 10.2174/2210681210666200213121156


Cancer is a leading cause of mortality, and its individual and collective impact is substantial. Conventional chemotherapy utilizes drugs that effectively destroy tumour cells. However, these agents destroy healthy cells along with the tumour cells, leading to many adverse effects, which include hypersensitivity reactions, nephrotoxicity, and neurotoxicity. To minimize these adverse effects, various drug delivery systems (DDSs) have been developed. Among them, nano drug delivery systems are particularly attractive platform. Thus, this review paper explores recent work on targeted delivery; tumour accumulation enhancement and sustained blood circulation using more effective biomaterials to enhance the properties of nanoparticles. Moreover, various target-specific drug delivery mechanisms, such as antibody-mediated delivery as well as the targeting of angiogenesis, mitochondria, and the CD44 receptor, are also explained. Read now:

Aims & Scope – Pharmaceutical Nanotechnology

ISSN (Print): 2211-7385
ISSN (Online): 2211-7393

Volume 10, Issue 5, 2022

Aims & Scope

Pharmaceutical Nanotechnology publishes original manuscripts, reviews, thematic issues, rapid technical notes and commentaries that provide insights into the synthesis, characterisation and pharmaceutical (or diagnostic) application of materials at the nanoscale. The nanoscale is defined as a size range of below 1 µm. Scientific findings related to micro and macro systems with functionality residing within features defined at the nanoscale are also within the scope of the journal. Manuscripts detailing the synthesis, exhaustive characterisation, biological evaluation, clinical testing and/ or toxicological assessment of nanomaterials are of particular interest to the journal’s readership. Articles should be self contained, centred around a well founded hypothesis and should aim to showcase the pharmaceutical/ diagnostic implications of the nanotechnology approach. Manuscripts should aim, wherever possible, to demonstrate the in vivo impact of any nanotechnological intervention. As reducing a material to the nanoscale is capable of fundamentally altering the material’s properties, the journal’s readership is particularly interested in new characterisation techniques and the advanced properties that originate from this size reduction. Both bottom up and top down approaches to the realisation of nanomaterials lie within the scope of the journal. Read now:

%d bloggers like this: